We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird Inks Genome Editing Research Deal With Novo Nordisk
Read MoreHide Full Article
bluebird bio, Inc. (BLUE - Free Report) announced that it has entered into a research collaboration agreement with Denmark’s Novo Nordisk A/S (NVO - Free Report) for jointly developing next-generation in vivo genome editing therapies for addressing genetic diseases including hemophilia.
The research collaboration will span over a period of three years and focus on developing a gene therapy candidate for offering hemophilia A patients with a lifetime free of factor replacement therapy. Financial terms of the deal were not disclosed.
The deal will leverage bluebird’s proprietary mRNA-based megaTAL gene editing technology with Novo Nordisk’s hemophilia portfolio. It will initially focus on correcting FVIII-clotting factor deficiency with the potential to explore additional therapies.
With this research pact, both companies are looking to develop a treatment to substantially reduce the burden of disease for patients with factor VIII deficiency. bluebird will get a strong partner in Novo Nordisk.
Shares of bluebird have lost 9.1% so far this year, compared with the industry’s decrease of 9.2%.
We remind investors that bluebird’s gene therapy gained ample attention of late. The objective of the therapy is to correct the underlying genetic defect, which is the cause of the disease rather than offering treatments that only address the symptoms.
In June 2019, the European Commission (EC) granted a conditional marketing authorization to Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene also known as LentiGlobinfor TDT), a gene therapy for patients aged 12 years or older with transfusion-dependent β-thalassemia (TDT). They do not have a β0/β0 genotype and for them hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. Zynteglo is bluebird’s first gene therapy to obtain a regulatory approval.
bluebird expects to initiate a rolling biologics licensing application submission for Zynteglo to the FDA pertaining to patients with TDT and non-β0/β0 genotypes by 2019 end.
Zacks Rank & Stocks to Consider
bluebird currently carries a Zacks Rank #4 (Sell).
Exact Sciences’ loss per share estimates have been narrowed 5.4% for 2019 and 10.1% for 2020 over the past 60 days. The stock has soared 44.3% year to date.
Incyte’s earnings estimates have moved 4.9% north for 2019 and 4.7% for 2020 over the past 60 days. The stock has rallied 17.4% year to date.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
bluebird Inks Genome Editing Research Deal With Novo Nordisk
bluebird bio, Inc. (BLUE - Free Report) announced that it has entered into a research collaboration agreement with Denmark’s Novo Nordisk A/S (NVO - Free Report) for jointly developing next-generation in vivo genome editing therapies for addressing genetic diseases including hemophilia.
The research collaboration will span over a period of three years and focus on developing a gene therapy candidate for offering hemophilia A patients with a lifetime free of factor replacement therapy. Financial terms of the deal were not disclosed.
The deal will leverage bluebird’s proprietary mRNA-based megaTAL gene editing technology with Novo Nordisk’s hemophilia portfolio. It will initially focus on correcting FVIII-clotting factor deficiency with the potential to explore additional therapies.
With this research pact, both companies are looking to develop a treatment to substantially reduce the burden of disease for patients with factor VIII deficiency. bluebird will get a strong partner in Novo Nordisk.
Shares of bluebird have lost 9.1% so far this year, compared with the industry’s decrease of 9.2%.
We remind investors that bluebird’s gene therapy gained ample attention of late. The objective of the therapy is to correct the underlying genetic defect, which is the cause of the disease rather than offering treatments that only address the symptoms.
In June 2019, the European Commission (EC) granted a conditional marketing authorization to Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene also known as LentiGlobinfor TDT), a gene therapy for patients aged 12 years or older with transfusion-dependent β-thalassemia (TDT). They do not have a β0/β0 genotype and for them hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. Zynteglo is bluebird’s first gene therapy to obtain a regulatory approval.
bluebird expects to initiate a rolling biologics licensing application submission for Zynteglo to the FDA pertaining to patients with TDT and non-β0/β0 genotypes by 2019 end.
Zacks Rank & Stocks to Consider
bluebird currently carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the healthcare sector include Exact Sciences Corporation (EXAS - Free Report) and Incyte Corporation (INCY - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Exact Sciences’ loss per share estimates have been narrowed 5.4% for 2019 and 10.1% for 2020 over the past 60 days. The stock has soared 44.3% year to date.
Incyte’s earnings estimates have moved 4.9% north for 2019 and 4.7% for 2020 over the past 60 days. The stock has rallied 17.4% year to date.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>